Connect with:
Thursday / January 30. 2025

logo
mobile-logo
HomePosts Tagged "Boehringer Ingelheim"
Agribusiness, Agrotech, India, Live Stock, Poultry, R&D

This represents a breakthrough in vaccine engineering and is recommended for in-ovo vaccination of chickens to protect against the virulent Marek’s disease.

Boehringer Ingelheim announced the launch of the latest advancement in Marek’s disease vaccines in India. This next generation vaccine offers enhanced protection through an innovative controlled attenuation process, delivering the right balance between safety and efficacy.

Marek’s disease remains a significant challenge in Indian poultry, with outbreaks continuing despite widespread vaccination efforts. The vaccine addresses this gap with a groundbreaking serotype-1 construct vaccine, offering an ideal balance of safety and efficacy against the most virulent strains.

Dr Vinod Gopal, Country Head-Animal Health, Boehringer Ingelheim India said, “Marek’s Disease presents a considerable risk, resulting in significant financial impact for poultry farmers, particularly affecting young chickens with immature immune systems. As India’s poultry industry expands, our vaccine is designed to aid farmers by reducing disease outbreaks, promoting flock health, and enhancing productivity. This innovative vaccine not only provides effective, early, and long-lasting immunity—supported by extensive trials across multiple regions—but also plays a crucial role in supporting food security and safety. It offers a cost-effective solution for poultry owners, helping to protect their livelihood while meeting the increasing demand for high-quality poultry products in India.”

Dr N.K Mahajan, Retired Professor and Head of Department of Veterinary Public Health and Epidemiology, LUVAS, Hisar, said “Marek’s disease continues to be a significant challenge for poultry farmers due to the increasing virulence of the virus strains. Even in the absence of clinical signs, Marek’s Disease virus can significantly damage chickens’ immune system as the virus attacks T lymphocytes. The resulting immunosuppression causes poor growth and performance, significantly affecting production and economics in the poultry industry. Birds are more prone to secondary infections and less responsive to other vaccines, leading to increased medication costs. The ability to provide early immunity and protection against the more aggressive forms of the virus is essential in reducing the impact of this disease on poultry farming operations in India.”

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries.

This represents a breakthrough in vaccine engineering

Agribusiness, Biofuel industry, Company News, Sustainability, Sustainable Energy, World

 Company will be able to cover 95 per cent of its energy requirements at the site from renewable sources in the future.

Boehringer Ingelheim inaugurated a biomass power plant at its Ingelheim site on Monday. With the new power plant, Boehringer Ingelheim is optimising its energy supply and protecting the environment at the same time: Around 50,000 tons of CO2 are saved per year. The CO2 emissions of the site’s own energy generation are reduced by 70 per cent. In total, the company is investing EUR 205 million in sustainable infrastructure projects in Ingelheim and will be able to cover 95 per cent of its energy requirements at the site from renewable sources in the future.

The Vice Chairman of the Board of Managing Directors, Michael Schmelmer, described the commissioning as a “significant milestone” for Boehringer Ingelheim and explained: “Part of our sustainability goals is to protect natural resources so that our earth remains a place worth living in for people and animals. With an environmentally friendly and more independent energy supply, we are ensuring stable production in order to be able to deliver medications for patients worldwide.”

The ceremonial inauguration was attended by the German Vice Chancellor and Federal Minister of Economics Robert Habeck and Rhineland-Palatinate Environment Minister Katrin Eder.

Federal Minister for Economic Affairs and Climate Action Robert Habeck said, “The decarbonization of all areas of our economy is necessary in order to achieve global climate targets on the one hand and a reduction in energy imports on the other. Boehringer Ingelheim is a good example of this. The company uses renewable energies for production. It trains and attracts talents as an attractive employer. Last but not least, it invests heavily in research and development, thus contributing to better healthcare and future proofing of the site.” Biomass is an important source of renewable energy and is considered almost CO2 neutral.

The waste wood used as fuel in Ingelheim is a waste product. It comes from the Rhine-Main area and is controlled according to strict quality standards.

Further measures for CO2 neutrality by 2030

The company has set itself the goal of making its business operations CO2 neutral by 2030. To this end, many individual projects are being implemented to save energy worldwide. By constructing more energy-efficient buildings, for example, the company has so far been able to save around 25% percent of its energy needs per square meter of floor space in Ingelheim. In Ingelheim, the company has also been operating its own solar park since 2023. Several other Boehringer Ingelheim sites are already certified as carbon neutral, for example in Dortmund (Germany), Gainesville (USA), Zhangjian (China) or Sant Cugat (Spain).

 Company will be able to cover 95

Agribusiness, Agrotech, Animal Health, Collaborations, Company News, Europe

Boehringer Ingelheim will use Veeva Vault CTMS in its Animal Health business unit to manage and monitor trials and Veeva Vault eTMF for real-time inspection preparation, visibility and control.

Veeva Systems announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications as the foundation for its technology for the clinical and regulatory management of its Animal Health division. By adopting unified applications on a single platform, Boehringer Ingelheim can streamline clinical execution to accelerate the development of new medicines that help animals live healthier, happier lives.

“The Veeva Vault Clinical and Veeva Vault RIM applications will help us improve operational efficiencies across functions while providing insights for data-driven decision-making. This will allow us to execute and innovate faster to improve the lives of animals”, said Marcus Gravendyck, Head of Global Regulatory Affairs and Pharmacovigilance, Animal Health, Boehringer Ingelheim.  

Boehringer Ingelheim will use Veeva Vault CTMS in its Animal Health business unit to manage and monitor trials and Veeva Vault eTMF for real-time inspection preparation, visibility and control. The company will also use Vault RIM applications, including Veeva Vault Registrations, Veeva Vault Submissions, and Veeva Vault Submissions Archive for advanced regulatory processes. Connecting these applications on a single cloud platform will enable real-time access to data and seamless information exchange.

“Boehringer Ingelheim drives innovation to accelerate the development of new treatments for animals,” said Thomas Reith, corporate vice president for informatics research, development and medicine at Boehringer Ingelheim. By building a centralized, digital foundation with Veeva, we can deliver a better user experience for our teams, as well as lean, end-to-end processes for speed and agility”.

“We are proud to partner with Boehringer Ingelheim in the animal health space to simplify their clinical development and regulatory processes,” said Stefan Jahnecke, vice president of animal health strategy at Veeva. Veeva Vault Clinical and Veeva Vault RIM will help Boehringer Ingelheim improve data integrity and provide the visibility needed to quickly adapt to changing business requirements.

Boehringer Ingelheim will use Veeva Vault CTMS